Find in Library

GLP-1 receptor agonists are a class of drugs with high efficacy, a good safety profile recommended as second-line drugs after metformin for the treatment of type 2 diabetes mellitus. Dulaglutide is a GLP-1 analogue designed for once weekly subcutaneous injection using recombinant technology and approved for use as monotherapy or in combination with other hypoglycemic agents in many countries. The randomized multicenter clinical trials have shown the advantage of dulaglutide monotherapy it had with respect to glycemic control over metformin in patients previously on diet therapy and no less efficacy compared with liraglutide monotherapy in daily injections. When used in combination with other hypoglycemic agents (including metformin, sulfonylurea preparations, metformin and pioglitazone, metformin and prandial insulin, insulin glargine), dulaglutide was no less effective than liraglutide at a dose of 1.8 mg per day and lowered the glycated hemoglobin level more significantly than sitagliptin, exenatide for injections twice a day and insulin glargine in the studies lasting 26–104 weeks. In this case, dulaglutide at a dose of 1.5 mg/week resulted in a weight loss lasting for two years of therapy. Dulaglutide was generally well tolerated, and a convenient disposable once-weekly self-injecting syringe-pen of the drug significantly improved the patient’s quality of life and encouraged adherence to therapy.